BioCentury | May 25, 2018
Clinical News

MimiVax reports Phase II data for glioblastoma immunotherapy

...in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. MimiVax...
...and maintenance SurVaxM every 12 weeks. Final data from the trial are expected in 4Q18. MimiVax...
...The product has Orphan Drug designation in the U.S. to treat glioblastoma and multiple myeloma. MimiVax LLC...
Items per page:
1 - 1 of 1
BioCentury | May 25, 2018
Clinical News

MimiVax reports Phase II data for glioblastoma immunotherapy

...in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. MimiVax...
...and maintenance SurVaxM every 12 weeks. Final data from the trial are expected in 4Q18. MimiVax...
...The product has Orphan Drug designation in the U.S. to treat glioblastoma and multiple myeloma. MimiVax LLC...
Items per page:
1 - 1 of 1